Epacadostat, Cladribine and Cytarabine (ECC) in AML
Condition(s):AML; RelapseLast Updated:September 11, 2018Withdrawn
Hide Studies Not Open or Pending
Condition(s):AML; RelapseLast Updated:September 11, 2018Withdrawn
Condition(s):Myelodysplastic Syndromes; Myeloproliferative Chronic Myelomonocytic LeukemiaLast Updated:January 16, 2024Recruiting
Condition(s):Acute Myeloid Leukemia; Elderly Patients; Newly DiagnosedLast Updated:December 17, 2020Unknown status
Condition(s):Acute Myeloid Leukemia; Myelodysplastic SyndromeLast Updated:April 6, 2023Recruiting
Condition(s):Langerhans Cell Histiocytosis of LungLast Updated:February 18, 2021Unknown status
Condition(s):Chronic Lymphocytic Leukaemia; Small Lymphocytic LymphomaLast Updated:January 31, 2018Terminated
Condition(s):Leukemia, Myelocytic, AcuteLast Updated:February 2, 2010Unknown status
Condition(s):Acute Myeloid Leukemia; Blasts 20 Percent or More of Bone Marrow Nucleated Cells; High Risk Myelodysplastic Syndrome; Recurrent Acute Biphenotypic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent High Risk Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory High Risk Myelodysplastic SyndromeLast Updated:November 30, 2023Recruiting
Condition(s):Lymphoma; Mantle Cell Lymphoma; Indolent Lymphoma; SLLLast Updated:December 30, 2019Completed
Condition(s):Acute Myeloid Leukemia; Myelodysplastic SyndromesLast Updated:February 20, 2024Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.